



CORRECTION

Author Correction: NRF2-GPX4/SOD2 axis imparts resistance to EGFR-tyrosine kinase inhibitors in non-small-cell lung cancer cells

Chun-shuang Ma¹, Qian-ming Lv¹, Ke-ren Zhang¹, Ya-bin Tang^{1,2}, Yu-fei Zhang¹, Ying Shen^{1,2}, Hui-min Lei^{1,2} and Liang Zhu^{1,2}
Acta Pharmacologica Sinica (2023) 44:2346; <https://doi.org/10.1038/s41401-023-01131-5>

Correction to: *Acta Pharmacologica Sinica* <https://doi.org/10.1038/s41401-020-0443-1>, published online 23 July 2020

A Western blot image in Fig. 6a (NRF2 protein expression in HCC827ER cells) was inadvertently misplaced in the process of

assembling figures. The correct version is shown. The corrigendum does not affect the interpretation of data and conclusions. The authors would like to apologize for any inconvenience this may have caused.




Fig. 6 NRF2-induced resistance to EGFR-TKIs depends on SOD2 and GPX4. **a** Western blot analysis of NRF2, GPX4, and SOD2 protein expression.

¹Department of Pharmacology and Chemical Biology, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China and ²Shanghai Collaborative Innovation Center for Translational Medicine, Shanghai 200025, China

Correspondence: Ying Shen (yshen0510@sjtu.edu.cn) or Hui-min Lei (leihuimin@shsmu.edu.cn) or Liang Zhu (jyzhu@shsmu.edu.cn)

These authors contributed equally: Chun-shuang Ma, Qian-ming Lv